time

[키워드] (Lopinavir/ritonavir adjusted Admission age Analysis antiviral drugs ARB Arbidol ARMS assigned Chest CT Clinical improvement contribute Corona virus cough COVID-19 COVID-19 disease criteria determine diagnosis of COVID-19 duration of hospitalization Dyspnea Effect effective Efficacy eligible patient ESR examined Fever Final final analysis followed by group groups Health Organization hospital Hospitalization Hydroxychloroquine ICU admissions IHD Improvements independent Kaletra Laboratory less Lopinavir Lopinavir/ritonavir male multicenter design Multiple linear regression multiple linear regression analysis Na level Open-label open-label randomized controlled trial oxygen oxygen saturation Patient patients with COVID-19 peripheral peripheral oxygen saturation Peripheral oxygen saturation rate Primary outcome Randomized controlled trial Randomly recruited relief Result Ritonavir Sample size significance level significantly supportive care Symptom the disease therapy time treatments for COVID-19 Trial registration two group two groups variable WBC WHO World Health Organization
[DOI] 10.1186/s12879-020-05698-w PMC 바로가기 [Article Type] Randomized Controlled Trial